- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05918523
A Long-Term Follow-Up Study of Participants Exposed to REACT
February 1, 2024 updated by: Prokidney
A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This observational extension study is a multi-center, prospective, non-therapeutic study, where up to 80 participants who have been enrolled and dosed with Renal Autologous Cell Therapy in previous interventional clinical studies (RMCL-002, REGEN-003, REGEN-004) will be monitored for up to five years with alternating in clinic and phone visits.
Study Type
Observational
Enrollment (Estimated)
80
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Beth Hilburger
- Phone Number: 336-999-7031
- Email: info@prokidney.com
Study Locations
-
-
Idaho
-
Meridian, Idaho, United States, 83642
- Recruiting
- Boise Kidney & Hypertension Institute
-
Principal Investigator:
- Arnold Silva, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
patients with CKD
Description
Inclusion Criteria:
- The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.
Exclusion Criteria:
- The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CKD patients previously treated with REACT
Participants Exposed to Renal Autologous Cell Therapy from studies RMCL-002, REGEN-003, REGEN-004 (REGEN-008S1).
|
No interventions in this trial
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Endpoint: Long-term safety of REACT
Time Frame: 60 months from completion of parent protocol EOS Visit
|
Evaluation of the long-term safety of REACT will be assessed via:
|
60 months from completion of parent protocol EOS Visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
First Secondary Endpoint: Time from first injection to eGFR <15 mL/min/1.73m²
Time Frame: 60 months from completion of parent protocol EOS Visit
|
Time from first injection to eGFR <15 mL/min/1.73m²
using the 2009 CKD-EPI serum creatinine equation.
|
60 months from completion of parent protocol EOS Visit
|
Second Secondary Endpoint: Time from first injection to chronic dialysis.
Time Frame: 60 months from completion of parent protocol EOS Visit
|
Time from first injection to chronic dialysis.
|
60 months from completion of parent protocol EOS Visit
|
Third Secondary Endpoint: Time from first injection to renal transplant.
Time Frame: 60 months from completion of parent protocol EOS Visit
|
Time from first injection to renal transplant.
|
60 months from completion of parent protocol EOS Visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Study Director, Prokidney
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 11, 2023
Primary Completion (Estimated)
January 1, 2028
Study Completion (Estimated)
March 1, 2028
Study Registration Dates
First Submitted
June 15, 2023
First Submitted That Met QC Criteria
June 15, 2023
First Posted (Actual)
June 26, 2023
Study Record Updates
Last Update Posted (Actual)
February 5, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Endocrine System Diseases
- Disease Attributes
- Diabetes Complications
- Diabetes Mellitus
- Renal Insufficiency
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Diseases
- Renal Insufficiency, Chronic
- Diabetic Nephropathies
Other Study ID Numbers
- REGEN-008S1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
Clinical Trials on Renal Autologous Cell Therapy (REACT)
-
ProkidneyActive, not recruitingChronic Kidney Diseases | Type 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedChronic Kidney Disease | Congenital Anomalies of Kidney and Urinary TractUnited States
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States
-
ProkidneyRecruitingChronic Kidney Diseases | Diabetic Kidney Disease | CAKUTUnited States
-
ProkidneyIqvia Pty LtdNot yet recruitingChronic Kidney Diseases | Type 2 Diabetes Mellitus
-
ProkidneyCTI Clinical Trial and Consulting ServicesCompletedType 2 Diabetes Mellitus | Chronic Kidney DiseaseUnited States
-
ProkidneyPPD; Iqvia Pty LtdActive, not recruitingChronic Kidney Diseases | Type 2 Diabetes MellitusUnited States, United Kingdom, Taiwan, Australia, Canada
-
Dr. Grant M. PagdinRecruitingOsteoarthritisCanada
-
Hospitales NisaUniversitat Politècnica de ValènciaCompletedStroke | Hemiparesis | Chronic Stroke | Upper Limb InjurySpain
-
University of Alabama at BirminghamCompleted